Literature DB >> 9403484

Butyrylcholinesterase in the life cycle of amyloid plaques.

A L Guillozet1, J F Smiley, D C Mash, M M Mesulam.   

Abstract

Deposits of diffuse beta-amyloid (Abeta) may exist in the brain for many years before leading to neuritic degeneration and dementia. The factors that contribute to the putative transformation of the Abeta amyloid from a relatively inert to a pathogenic state remain unknown and may involve interactions with additional plaque constituents. Matching brain sections from 2 demented and 4 nondemented subjects were processed for the demonstration of Abeta immunoreactivity, butyrylcholinesterase (BChE) enzyme activity, and thioflavine S binding. Additional sections were processed for the concurrent demonstration of two or three of these markers. A comparative analysis of multiple cytoarchitectonic areas processed with each of these markers indicated that Abeta plaque deposits are likely to undergo three stages of maturation, ie, a "diffuse" thioflavine S-negative stage, a thioflavine S-positive (ie, compact) but nonneuritic stage, and a compact neuritic stage. A multiregional analysis showed that BChE-positive plaques were not found in cytoarchitectonic areas or cortical layers that contained only the thioflavine S-negative, diffuse type of Abeta plaques. The BChE-positive plaques were found only in areas containing thioflavine S-positive compact plaques, both neuritic and nonneuritic. Within such areas, almost all (>98%) BChE-containing plaques bound thioflavine S, and almost all (93%) thioflavine S plaques contained BChE. These results suggest that BChE becomes associated with amyloid plaques at approximately the same time that the Abeta deposit assumes a compact beta-pleated conformation. BChE may therefore participate in the transformation of Abeta from an initially benign form to an eventually malignant form associated with neuritic tissue degeneration and clinical dementia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403484     DOI: 10.1002/ana.410420613

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  67 in total

1.  Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases.

Authors:  Sultan Darvesh; Ryan Walsh; Earl Martin
Journal:  Cell Mol Neurobiol       Date:  2003-02       Impact factor: 5.046

2.  Synthesis and preliminary evaluation of piperidinyl and pyrrolidinyl iodobenzoates as imaging agents for butyrylcholinesterase.

Authors:  Ian R Macdonald; G Andrew Reid; E Eric Joy; Ian R Pottie; Gilbert Matte; Steven Burrell; George Mawko; Earl Martin; Sultan Darvesh
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

3.  Acetylcholinesterase Inhibitors: Treatment of Dementia-Related Behavioral Disturbances.

Authors:  Sanjay Gupta; Prakash Masand; Subhdeep Virk
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-12

4.  Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Hiroyasu Akatsu; Eric E Abrahamson; Zhiping Mi; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2015-08-21       Impact factor: 1.906

5.  Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model.

Authors:  Chun-Yan Wang; Wei Zheng; Tao Wang; Jing-Wei Xie; Si-Ling Wang; Bao-Lu Zhao; Wei-Ping Teng; Zhan-You Wang
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

Review 6.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.

Authors:  Mohammad A Kamal; Peter Klein; Weiming Luo; Yazhou Li; Harold W Holloway; David Tweedie; Nigel H Greig
Journal:  Neurochem Res       Date:  2007-11-06       Impact factor: 3.996

Review 8.  Rivastigmine. A review of its use in Alzheimer's disease.

Authors:  C M Spencer; S Noble
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

9.  Amyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum.

Authors:  R T Robertson; J Baratta; J Yu; F M LaFerla
Journal:  Neuroscience       Date:  2009-09-20       Impact factor: 3.590

Review 10.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.